Solu Ther­a­peu­tics

In antibody therapy, researchers create custom-made antibodies that bind to cells such as tumor cells, flagging them for destruction by the immune system. It’s a powerful technology — but for some types of cells, there’s nowhere to attach an antibody. Solu Ther­a­peu­tics literally bridges this gap using proprietary molecules called Cyto­tox­i­city Targeting Chimeras (CyTaCs) that attach to target cells on one end and antibodies on the other. The company’s first clinical candidate will target blood cancers.